What's New in 2025

Position Paper "Toward Advancement and Value Enhancement of Medicine and Pharmaceuticals Co-Created with Patients"-Patient-Reported Outcome (PRO) Assessment as a Permanent
is now available.

Position Paper " Survey on Emerging Biopharma Companies (EBPs) with Developmental Products in Japan"
is now available.

OPIR Views and Actions No.76 is now available.

The article on the Institute for Policy Studies was published in "Toward the Era of Co-Creation," a series of articles by the JPMA Committee of the Nikkan Yakugyo (Daily Pharmaceutical Journal).
<No.17> "Contributing to the Study of Industry Issues with Evidence" The Office of Pharmaceutical Industry Research

Please refer to the link for details.

Position Paper "Survey on EBP-derived drugs in the U.S.
A Comparison of Biotech and Small Molecule Products
is now available.

Position Paper "Survey Report of Pharmaceutical Companies on Utilization of Public Databases, etc.
from OPIR Views and ActionsNo.75" is now available.
is now available.

OPIR Views and Actions No.75 is now available.

The Office of Pharmaceutical Industry Research Dr. Sadao Nagaoka, former director and current research advisor, received the 5th
Dr. Sadao Nagaoka, former director and current research advisor, received the 5th Nakamura Takahide Award from the Japan Statistical Society.
The reason for the award is that Dr. Nagaoka's achievements and pioneering work in innovation research using statistical analysis have been highly evaluated internationally.
The reason for the award is that Dr. Nagaoka's innovation research results and pioneering work using statistical analysis have been highly evaluated internationally.
We congratulate Dr. Nagaoka for receiving this award. Please see the link for details.

An overseas paper submitted by IPSJ has been published.
Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies
(Research Paper No.82 "The State of Pharmaceutical R&D: R&D Duration, Probability of Success, and R&D Costs Based on a Questionnaire Survey")

Research Institute Profile page has been updated.

Research Paper No.85 is now available.

OPIR Views and ActionsNo.74 is now available.

Position Paper "A Consideration of the NHI Calculation Rules for Evaluating the Value of Drugs
A follow-up to Position Paper No. 3, "Challenges for the Valuation System as the Value of Drugs Changes.
is now available.